These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 19840788

  • 21. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis.
    Gresle MM, Shaw G, Jarrott B, Alexandrou EN, Friedhuber A, Kilpatrick TJ, Butzkueven H.
    J Neurosci Res; 2008 Dec; 86(16):3548-55. PubMed ID: 18709652
    [Abstract] [Full Text] [Related]

  • 22. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.
    Bjartmar C, Kidd G, Mörk S, Rudick R, Trapp BD.
    Ann Neurol; 2000 Dec; 48(6):893-901. PubMed ID: 11117546
    [Abstract] [Full Text] [Related]

  • 23. Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis.
    Singh S, Dallenga T, Winkler A, Roemer S, Maruschak B, Siebert H, Brück W, Stadelmann C.
    J Neuroinflammation; 2017 Mar 17; 14(1):57. PubMed ID: 28302146
    [Abstract] [Full Text] [Related]

  • 24. Molecular mechanisms of axonal damage in inflammatory central nervous system diseases.
    Neumann H.
    Curr Opin Neurol; 2003 Jun 17; 16(3):267-73. PubMed ID: 12858061
    [Abstract] [Full Text] [Related]

  • 25. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
    Parry A, Corkill R, Blamire AM, Palace J, Narayanan S, Arnold D, Styles P, Matthews PM.
    J Neurol; 2003 Feb 17; 250(2):171-8. PubMed ID: 12574947
    [Abstract] [Full Text] [Related]

  • 26. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis.
    Linker RA, Lee DH, Demir S, Wiese S, Kruse N, Siglienti I, Gerhardt E, Neumann H, Sendtner M, Lühder F, Gold R.
    Brain; 2010 Aug 17; 133(Pt 8):2248-63. PubMed ID: 20826430
    [Abstract] [Full Text] [Related]

  • 27. Evaluating the evidence for multiple sclerosis as an autoimmune disease.
    Altmann D.
    Arch Neurol; 2005 Apr 17; 62(4):688; author reply 688-9. PubMed ID: 15824275
    [No Abstract] [Full Text] [Related]

  • 28. Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice.
    Onuki M, Ayers MM, Bernard CC, Orian JM.
    Microsc Res Tech; 2001 Mar 15; 52(6):731-9. PubMed ID: 11276125
    [Abstract] [Full Text] [Related]

  • 29. Early glial responses in murine models of multiple sclerosis.
    Ayers MM, Hazelwood LJ, Catmull DV, Wang D, McKormack Q, Bernard CC, Orian JM.
    Neurochem Int; 2004 Mar 15; 45(2-3):409-19. PubMed ID: 15145555
    [Abstract] [Full Text] [Related]

  • 30. Immunologic aspects of multiple sclerosis.
    Boppana S, Huang H, Ito K, Dhib-Jalbut S.
    Mt Sinai J Med; 2011 Mar 15; 78(2):207-20. PubMed ID: 21425265
    [Abstract] [Full Text] [Related]

  • 31. High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord.
    DeBoy CA, Zhang J, Dike S, Shats I, Jones M, Reich DS, Mori S, Nguyen T, Rothstein B, Miller RH, Griffin JT, Kerr DA, Calabresi PA.
    Brain; 2007 Aug 15; 130(Pt 8):2199-210. PubMed ID: 17557778
    [Abstract] [Full Text] [Related]

  • 32. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease.
    Bjartmar C, Wujek JR, Trapp BD.
    J Neurol Sci; 2003 Feb 15; 206(2):165-71. PubMed ID: 12559505
    [Abstract] [Full Text] [Related]

  • 33. Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis.
    Waxman SG.
    Trends Mol Med; 2006 May 15; 12(5):192-5. PubMed ID: 16574486
    [Abstract] [Full Text] [Related]

  • 34. Immune-mediated CNS damage.
    Kierdorf K, Wang Y, Neumann H.
    Results Probl Cell Differ; 2010 May 15; 51():173-96. PubMed ID: 19130024
    [Abstract] [Full Text] [Related]

  • 35. Grey matter pathology in multiple sclerosis.
    Geurts JJ, Barkhof F.
    Lancet Neurol; 2008 Sep 15; 7(9):841-51. PubMed ID: 18703006
    [Abstract] [Full Text] [Related]

  • 36. Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology.
    Lee JY, Biemond M, Petratos S.
    Neurodegener Dis Manag; 2015 Dec 15; 5(6):527-48. PubMed ID: 26619755
    [Abstract] [Full Text] [Related]

  • 37. Modeling a complex disease: multiple sclerosis.
    Kurschus FC, Wörtge S, Waisman A.
    Adv Immunol; 2011 Dec 15; 110():111-37. PubMed ID: 21762817
    [Abstract] [Full Text] [Related]

  • 38. Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions.
    Sättler MB, Demmer I, Williams SK, Maier K, Merkler D, Gadjanski I, Stadelmann C, Bähr M, Diem R.
    Exp Neurol; 2006 Sep 15; 201(1):172-81. PubMed ID: 16764858
    [Abstract] [Full Text] [Related]

  • 39. Future neuroprotective strategies.
    Sättler MB, Bähr M.
    Exp Neurol; 2010 Sep 15; 225(1):40-7. PubMed ID: 19716365
    [Abstract] [Full Text] [Related]

  • 40. The role of mitochondria in axonal degeneration and tissue repair in MS.
    van Horssen J, Witte ME, Ciccarelli O.
    Mult Scler; 2012 Aug 15; 18(8):1058-67. PubMed ID: 22723572
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.